Insider Selling: InspireMD (NYSE:NSPR) Insider Sells $20,451.75 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 12,395 shares of InspireMD stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $1.65, for a total value of $20,451.75. Following the transaction, the insider owned 1,149,077 shares in the company, valued at approximately $1,895,977.05. This represents a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shane Thomas Gleason also recently made the following trade(s):

• On Monday, February 2nd, Shane Thomas Gleason sold 2,000 shares of InspireMD stock. The shares were sold at an average price of $1.60, for a total transaction of $3,200.00.
• On Friday, January 30th, Shane Thomas Gleason sold 2,900 shares of InspireMD stock. The stock was sold at an average price of $1.63, for a total transaction of $4,727.00.
• On Thursday, January 29th, Shane Thomas Gleason sold 5,000 shares of InspireMD stock. The shares were sold at an average price of $1.65, for a total transaction of $8,250.00.
• On Tuesday, January 27th, Shane Thomas Gleason sold 4,781 shares of InspireMD stock. The shares were sold at an average price of $1.66, for a total transaction of $7,936.46.
• On Thursday, January 22nd, Shane Thomas Gleason sold 8,411 shares of InspireMD stock. The stock was sold at an average price of $1.57, for a total transaction of $13,205.27.
• On Wednesday, January 21st, Shane Thomas Gleason sold 17,593 shares of InspireMD stock. The shares were sold at an average price of $1.62, for a total transaction of $28,500.66.
• On Tuesday, January 20th, Shane Thomas Gleason sold 2,955 shares of InspireMD stock. The shares were sold at an average price of $1.59, for a total value of $4,698.45.
• On Friday, January 16th, Shane Thomas Gleason sold 2,250 shares of InspireMD stock. The stock was sold at an average price of $1.61, for a total value of $3,622.50.
• On Thursday, January 15th, Shane Thomas Gleason sold 2,909 shares of InspireMD stock. The stock was sold at an average price of $1.58, for a total value of $4,596.22.

InspireMD Stock Down 0.1%

Shares of InspireMD stock opened at $1.64 on Thursday. The firm has a market cap of $69.45 million, a PE ratio of -2.19 and a beta of 0.93. InspireMD, Inc. has a 52 week low of $1.51 and a 52 week high of $3.80. The business’s fifty day simple moving average is $1.81 and its 200-day simple moving average is $2.15.

Wall Street Analysts Forecast Growth

Separately, Maxim Group started coverage on shares of InspireMD in a research note on Monday. They issued a “buy” rating and a $6.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InspireMD has an average rating of “Buy” and a consensus price target of $5.00.

Hedge Funds Weigh In On InspireMD

A number of hedge funds and other institutional investors have recently bought and sold shares of NSPR. Aberdeen Group plc acquired a new stake in shares of InspireMD during the third quarter worth about $5,979,000. Rosalind Advisors Inc. increased its stake in InspireMD by 70.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after buying an additional 1,616,644 shares during the period. Velan Capital Investment Management LP increased its stake in InspireMD by 137.1% during the 3rd quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock worth $5,166,000 after buying an additional 1,239,669 shares during the period. Parkman Healthcare Partners LLC lifted its holdings in InspireMD by 97.6% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after buying an additional 1,205,328 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its position in InspireMD by 45.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after buying an additional 1,058,467 shares during the period. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.